What GHK-Cu is

GHK-Cu is a naturally-occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) discovered in the 1970s by Dr. Loren Pickart. It circulates in human plasma at nanomolar concentrations that decline sharply with age — from roughly 200 ng/mL at age 20 to around 80 ng/mL by age 60. That age-associated decline is what drives most of the regenerative-medicine and cosmetic-science interest in the peptide.

The copper-bound form (GHK-Cu²⁺) is the biologically active species. The apo-peptide (GHK without copper) has substantially less activity in most published assays.

Mechanism of action

Published mechanisms span three overlapping areas:

• Extracellular matrix remodeling — GHK-Cu upregulates decorin, collagen I/III synthesis, and MMP/TIMP balance in dermal fibroblast culture. This is the mechanism most cited in cosmetic-science literature.
• Copper trafficking and antioxidant defense — the peptide donates and shuttles Cu²⁺ to Cu/Zn-SOD, ceruloplasmin, and lysyl oxidase, and modulates copper-dependent enzymes involved in cross-linking and radical detoxification.
• Gene-expression modulation — Broad Institute transcriptome data (Pickart et al., 2015) reported GHK-Cu modulates roughly 4,000 human genes at physiological concentrations, with strong enrichment in DNA-repair, anti-inflammatory, and stem-cell pathways.

Published research findings

• Multiple dermal fibroblast and hair-follicle culture studies report GHK-Cu upregulates decorin, collagen, and integrin expression.
• Wound-healing models (rodent, porcine) report faster closure with topical GHK-Cu formulations.
• Hair-follicle dermal papilla culture (Pyo et al.) reports enlarged follicle size and VEGF induction.
• Anti-inflammatory activity in TNF-α-stimulated cell lines is well documented.

Routes reported in research

• Topical — the dominant route in cosmetic-science literature (0.05%–2% GHK-Cu in a suitable vehicle).
• Subcutaneous injection — used in some regenerative-medicine research protocols.
• Scalp micro-injection — reported for hair-regrowth models.

Dosing ranges reported in the literature

Injectable protocols in the peptide-research literature typically discuss 1–2 mg subcutaneous, 3–5 times per week. Topical formulations use 100–500 mg per bottle of serum at concentrations in the 0.05%–2% range. Concurrent copper supplementation is not required — the peptide traffics its own Cu²⁺ from serum.

Blends and stacking discussed in the literature

• GLOW — GHK-Cu + BPC-157 + TB-500 — the canonical skin/regenerative research blend.
• KLOW — Kisspeptin + Larazotide + Oxytocin + GHK-Cu — a broader-spectrum blend.
• GHK-Cu + copper-nutrient support in dermal formulations.

Standard laboratory handling

Every research vial from PX1 is a lyophilized (freeze-dried) powder sealed under vacuum in a Type-I borosilicate vial with a butyl-rubber stopper and aluminum crimp seal. Correct handling preserves potency and prevents peptide-bond hydrolysis that degrades the active molecule.

• Storage before reconstitution: 2–8 °C refrigerator is ideal; freezer (−20 °C) for storage beyond six months. Short excursions to room temperature during shipping do not compromise integrity — the compound is stable in its solid state.
• Reconstitution solvent: bacteriostatic water for injection (0.9% benzyl alcohol) is standard for research protocols that require multiple sampling events from the same vial. Sterile water is acceptable for single-use protocols.
• Reconstitution technique: inject the diluent slowly against the vial wall — never directly onto the lyophilized cake. Swirl gently; do not shake. Shaking introduces air, denatures peptide secondary structure, and can create insoluble aggregates.
• Post-reconstitution storage: 2–8 °C refrigerated, typically stable 21–30 days depending on the peptide. Freezing a reconstituted solution repeatedly is not recommended — freeze/thaw cycles are the single biggest driver of loss-of-potency in the research literature.
• Concentration math: volume of diluent (mL) = peptide mass (mg) ÷ desired concentration (mg/mL). Example: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.

Purity, identity and COA verification

The single most important due-diligence step when sourcing GHK-Cu (copper tripeptide) for research is reviewing the lot-specific Certificate of Analysis (COA). A credible COA contains:

1. HPLC purity value with chromatogram — target ≥ 98% for injectable-grade research peptides; ≥ 99% for the newest generation of GLP/incretin compounds. A single well-defined main peak with baseline separation from impurities is what you are looking for.
2. Identity confirmation by mass spectrometry — LC-MS or MALDI-TOF confirming the observed molecular weight matches the theoretical mass to within instrument tolerance.
3. Endotoxin (LAL / kinetic-chromogenic) result — expressed in EU/mg; USP guidance for parenteral products is well below 5 EU/kg body-weight equivalent, and reputable suppliers report < 10 EU/mg on the COA.
4. Sterility result — USP <71> membrane filtration or direct inoculation, both bacterial and fungal.
5. Karl Fischer moisture — target < 5% residual water for a properly lyophilized cake.
6. Residual-solvent screen — DMF, TFA, DCM, acetonitrile below ICH Q3C thresholds.

PX1 publishes lot-specific COAs at /purity-reports. If you have received a shipment and want to verify the exact lot documentation for GHK-Cu (copper tripeptide), cross-reference the lot number on the vial label to the COA PDF.

Why researchers choose PX1 for GHK-Cu (copper tripeptide)

• 100% U.S. synthesis, lyophilization, and fill/finish. No repackaged imports. Every step from raw amino acid to sealed vial happens under one U.S. GMP-compliant roof.
• Third-party ISO-17025 testing on every lot. Purity, identity, endotoxin, sterility, moisture, and residual-solvent testing performed by an independent analytical laboratory whose data appears on the shipped COA.
• Chain-of-custody documentation from raw material through final QC — the same documentation package a clinical CDMO would provide.
• Same-day shipping on in-stock catalog items ordered before 3 p.m. ET, with insulated packaging and cold-pack where appropriate.

Common researcher questions

Q: How do I know the vial contents match the label? Compare the lot number on the vial to the lot number on the COA. The COA lists HPLC purity, identity by mass-spec, and endotoxin. If any of the three is missing or the lot doesn't match, don't proceed.

Q: Can I use bacteriostatic water past its printed expiration? Bacteriostatic water carries a manufacturer-assigned expiration for the sealed vial. Once punctured, USP guidance limits multi-dose vials to 28 days at 2–8 °C. Beyond 28 days, discard.

Q: Is refrigeration required during shipping? For most lyophilized peptides, no — the solid form is stable at ambient temperature for weeks. Some compounds (IGF-1 LR3, certain GH-releasing peptides) benefit from cold-chain shipping. PX1 uses insulated packaging for temperature-sensitive lines.

Q: What if the reconstituted solution is cloudy? Cloudiness indicates aggregation or precipitation and the solution should not be used. Common causes: over-vigorous shaking, incompatible diluent, or a vial that has passed its stability window.

Research use disclaimer

GHK-Cu (copper tripeptide) is supplied to licensed research professionals for in vitro and in vivo laboratory research only. Products are not intended for human consumption, veterinary use, diagnostic use, therapeutic use, or as a food additive or cosmetic. Nothing on this page constitutes medical advice. Consult the primary literature — clinical-trial registrations, peer-reviewed publications — before designing any protocol. Compounds discussed here are investigational; several have not received FDA approval for any indication.

Additional PX1 references

• Complete research library
• Lot-specific purity reports
• Product catalog
• Manufacturing & QC standards